KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short-term Investments: 2009-2025

Historic Short-term Investments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $227.7 million.

  • Biomarin Pharmaceutical's Short-term Investments fell 10.69% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year decrease of 10.69%. This contributed to the annual value of $194.9 million for FY2024, which is 38.85% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Short-term Investments of $227.7 million as of Q3 2025, which was up 4.32% from $218.3 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Short-term Investments ranged from a high of $572.0 million in Q1 2023 and a low of $194.9 million during Q4 2024.
  • In the last 3 years, Biomarin Pharmaceutical's Short-term Investments had a median value of $255.0 million in 2024 and averaged $307.2 million.
  • In the last 5 years, Biomarin Pharmaceutical's Short-term Investments surged by 32.91% in 2022 and then plummeted by 47.63% in 2024.
  • Biomarin Pharmaceutical's Short-term Investments (Quarterly) stood at $426.6 million in 2021, then spiked by 32.91% to $567.0 million in 2022, then plummeted by 43.80% to $318.7 million in 2023, then plummeted by 38.85% to $194.9 million in 2024, then fell by 10.69% to $227.7 million in 2025.
  • Its Short-term Investments stands at $227.7 million for Q3 2025, versus $218.3 million for Q2 2025 and $223.5 million for Q1 2025.